Yuyan Tang | Immunology and Microbiology | Best Researcher Award

Published on by Forensic Scientist

Prof. Yuyan Tang | Immunology and Microbiology | Best Researcher Award

Minhang Hospital, Fudan University | China

Prof. Yuyan Tang is a clinician-scientist specializing in nephrology and molecular immunopathology, with a strong research focus on the gut–kidney axis, IgA nephropathy, and chronic kidney disease (CKD). Her studies elucidate the mechanisms by which intestinal microbiota, short-chain fatty acids (SCFAs), and NLRP3 inflammasome signaling influence renal inflammation and fibrosis, integrating molecular biology with traditional Chinese medicine interventions. She has led several competitive research projects funded by the National Natural Science Foundation of China and regional scientific bodies, advancing translational insights into renal disease mechanisms and microbiome-based therapeutic strategies. Prof. Yuyan Tang has published 23 peer-reviewed documents indexed in Scopus, garnering 287 citations across 262 citing documents, with an h-index of 8. Her scientific contributions include 8 first- or corresponding-author SCI papers with a total impact factor of 52.7, notably featuring a highly cited article in Circulation Research and impactful publications in Nephrology Dialysis Transplantation and BMC Microbiology. Recognized as a Youth Talent Awardee at Fudan University’s Affiliated Minhang Hospital, Prof. Yuyan Tang’s research continues to bridge microbiome regulation and nephrology through innovative molecular and clinical investigations.

Profile: Scopus

Featured Publications

  • Tang, Y., Zhu, Y., He, H., Sun, W., Wu, J., Xiao, Y., … Xu, X. (2024). IgA nephropathy: Gut microbiome regulates the production of hypoglycosylated IgA1 via the TLR4 signaling pathway. Nephrology Dialysis Transplantation, 39(10), 1624–1641.

  • Jiang, L., He, H., Tang, Y., Li, J., Reilly, S., Xin, H., … Cai, H. (2024). Activation of BK channels prevents diabetes-induced osteopenia by regulating mitochondrial Ca2+ and SLC25A5/ANT2-PINK1-PRKN-mediated mitophagy. Autophagy, 20(11), 2388–2404.

  • Li, H., Xu, M., Xu, X., Tang, Y., Jiang, H., Li, L., … Yang, T. (2022). Faecalibacterium prausnitzii attenuates CKD via Butyrate-Renal GPR43 Axis. Circulation Research, 131(9), e120–e134.

  • Tang, Y., Xiao, Y., He, H., Zhu, Y., Sun, W., Hu, P., … Xu, X. (2023). Aberrant gut microbiome contributes to barrier dysfunction, inflammation and local immune responses in IgA nephropathy. Kidney and Blood Pressure Research, 48(1), 261–276.

  • Tang, Y., Zhu, Y., He, H., Peng, Y., Hu, P., Wu, J., … Xu, X. (2022). Gut dysbiosis and intestinal barrier dysfunction promote IgA nephropathy by increasing the production of Gd-IgA1. Frontiers in Medicine, 9, 944027.

Majid Taati Moghadam | Immunology and Microbiology | Best Researcher Award

Published on by Forensic Scientist

Assist. Prof. Dr. Majid Taati Moghadam | Immunology and Microbiology | Best Researcher Award

Guilan University of Medical Sciences | Iran

Dr. Majid Taati Moghadam is a dedicated Medical Microbiologist and Antimicrobial Resistance Researcher based in Rasht, Iran. He specializes in microbial pathogenesis, antibiotic resistance mechanisms, bacteriophage therapy, and the connection between microbiota and neurodegenerative disorders. His multidisciplinary expertise extends across clinical microbiology, infectious disease prevention, and translational therapeutics, making him a leading figure in Iran’s microbiological research community.

Professional Profile

Scopus

Google Scholar

ORCID

Education

Dr. Majid Taati holds a Ph.D. in Medical Bacteriology from Iran University of Medical Sciences (2017–2022), where his research investigated the relationship between oral microbiome shifts and Alzheimer’s disease. He earned his Master’s degree in Medical Microbiology from Kerman University of Medical Sciences (2012–2015), focusing on carbapenem resistance genes in Klebsiella pneumoniae. His academic journey began with a Bachelor’s degree in Microbiology from Islamic Azad University, Lahijan Branch (2007–2012). Throughout his studies, he demonstrated a keen interest in antibiotic resistance, clinical diagnostics, and the molecular biology of pathogens.

Experience

Dr. Majid Taati has played key roles in over a dozen microbiological research projects across Iran. As both a principal investigator and main collaborator, he has contributed to studies on extended-spectrum beta-lactamase (ESBL) genes, resistance enzymes in E. coli, and the antimicrobial effects of plant extracts like Ephedra pachyclada. He has worked extensively on projects involving nosocomial infections, multidrug-resistant bacteria, and genetic analysis methods such as MLVA and HRM techniques. He also authored the textbook Essential Medical Microbiology in Persian, and presented his findings at several major Iranian congresses, including the International Microbiology Congress. His laboratory and academic experience bridges both applied research and educational leadership.

Research Interests

Dr. Majid Taati research focuses on antimicrobial resistance mechanisms, phage and endolysin therapy, bacterial biofilm inhibition, and engineered phage enzymes for resistant infections. He is also deeply involved in exploring the role of microbiota in neurological and neuropsychiatric disorders, especially Alzheimer’s disease. His studies aim to bridge clinical microbiology with therapeutic innovation addressing global health threats posed by superbugs like carbapenem- and colistin-resistant Gram-negative bacteria. His recent projects extend to wound healing biomaterials, phage protein therapies, and microbiome-based diagnostics, reflecting his broad and multidisciplinary scientific interests.

Awards

Recognized for his extensive research contributions, Dr. Majid Taati is a deserving nominee for the “Best Researcher Award” in medical microbiology and antimicrobial resistance. His scholarly excellence, particularly in phage therapy and resistance gene profiling, aligns well with the objectives of scientific bodies that honor groundbreaking research. With dozens of publications in top-tier journals and continuous involvement in nationally significant projects, he exemplifies leadership in translational microbiology and global infectious disease research.

Publications

  • Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis
    Year: 2020
    Citations: 316

  • Bacteriophage therapy against Pseudomonas aeruginosa biofilms: a review
    Year: 2020
    Citations: 311

  • How phages overcome the challenges of drug resistant bacteria in clinical infections
    Year: 2020
    Citations: 173

  • Bacteriophages, a new therapeutic solution for inhibiting multidrug-resistant bacteria causing wound infection: lesson from animal models and clinical trials
    Year: 2020
    Citations: 125

  • COVID-19 (Coronavirus disease 2019): a new coronavirus disease
    Year: 2020
    Citations: 108

  • Evaluation of Nano-curcumin effects on expression levels of virulence genes and biofilm production of multidrug-resistant Pseudomonas aeruginosa isolated from clinical samples
    Year: 2019
    Citations: 108

  • Bacteriophage as a novel therapeutic weapon for killing colistin-resistant multi-drug-resistant and extensively drug-resistant gram-negative bacteria
    Year: 2021
    Citations: 58

Conclusion

Dr. Majid Taati Moghaddam Ziabari has built an impressive career defined by scientific innovation, deep academic rigor, and a commitment to combating infectious diseases. His pioneering work in bacteriophage therapy and antimicrobial resistance not only advances microbiological science but also addresses some of the most urgent global health challenges. With his rich publication record, research leadership, and academic influence, he is a prime candidate for international recognition, especially the Best Researcher Award. His career serves as a model of excellence in translational research and academic impact.

Yun zou | Microbiology | Best Researcher Award

Published on by Forensic Scientist

Mr. Yun zou | Microbiology | Best Researcher Award

The General Hospital of Western Theater Command | China

Zou Xinyun is a Master’s degree candidate and Chief Technician with a strong background in oncology and biomedical engineering. Since graduating from Hubei University of Science and Technology in 2011, he has been dedicated to medical research and clinical practice at the General Hospital of the Western Theater Command of the Chinese People’s Liberation Army. Currently, he is pursuing his Master’s degree in Biomedical Engineering at the School of Medicine, Southwest Jiaotong University, under the guidance of Professor Zhang Ling. His research contributions have been recognized through multiple prestigious awards and numerous scientific publications.

Profile👤

ORCID

Strengths for the Awards✨

  • Extensive Research Contributions 📚

    • Zou Xinyun has published five SCI papers as the first author in reputable journals, including Translational Cancer Research, Discover Oncology, and Clinical and Experimental Hypertension.
    • He has also co-authored several other publications, demonstrating his active involvement in collaborative research.

  • Academic Excellence & Recognition 🎓

    • He is a National Graduate Scholarship recipient, which highlights his academic excellence and dedication to research.
    • Recognized as an Outstanding Graduate of Hubei University of Science and Technology and an Excellent Medical Worker at his hospital, indicating his exceptional contributions to both research and clinical practice.

  • Strong Clinical and Research Background 🏥

    • With over a decade of experience at the Department of Oncology in a leading military hospital, he has gained deep expertise in clinical oncology research.
    • His ongoing Master’s in Biomedical Engineering at Southwest Jiaotong University under Professor Zhang Ling demonstrates a strong interdisciplinary approach to cancer research.
  • Zou Xinyun has an impressive research profile, particularly in oncology and biomedical engineering, with multiple SCI-indexed publications, academic excellence awards, and clinical research experience. While he is a strong candidate for the Best Researcher Award, focusing on high-impact publications, independent funding, and broader collaborations could further solidify his position as a top-tier researcher in his field.

🎓 Education

  • Bachelor’s Degree (2011) – Hubei University of Science and Technology
  • Master’s Degree Candidate (2021–2024) – School of Medicine, Southwest Jiaotong University
    • Research supervised by Professor Zhang Ling
    • Specializing in Biomedical Engineering

🏥 Experience

  • 2011–Present: Chief Technician, Department of Oncology, General Hospital of the Western Theater Command, Chinese People’s Liberation Army
    • Over a decade of experience in oncology research and clinical applications
    • Involved in advanced medical diagnostics and cancer treatment strategies

🔬 Research Interests On Microbiology

Zou Xinyun’s research focuses on oncology, biomedical engineering, and clinical cancer treatment. His work explores innovative approaches in cancer diagnostics, therapeutic interventions, and biomedical applications to improve patient outcomes. He is particularly interested in translational cancer research and the development of novel treatment methodologies.

🏆 Awards & Honors

  • 🏅 Outstanding Graduate – Hubei University of Science and Technology
  • 🏅 Excellent Medical Worker – General Hospital of the Western Theater Command
  • 🏅 National Graduate Scholarship – Recognized for academic excellence and research contributions

📚 Publications

  • Title: Association between immune cells and endometrial cancer: A bidirectional Mendelian randomization study

    • Authors: Xinyun Zou, Jinlan Shen, Hengdi Zhang, Fangyuan Kong, Xuemei Jin, Ling Zhang
    • Year: 2024
    • Citations: Not provided

  • Title: The causal effects of immune cells on pancreatic cancer: A 2‑sample Mendelian randomization study

    • Authors: Zou X, Shen J, Yong X, Diao Y, Ling Zhang
    • Year: 2024
    • Citations: Not provided

  • Title: Emodin ameliorates myocardial fibrosis in mice by inactivating the ROS/PI3K/Akt/mTOR axis

    • Authors: Huang W, Zhou P, Zou X, Liu Y, Zhou L, Zhang Y
    • Year: 2024
    • Citations: Not provided

  • Title: Radiomics in Nasopharyngeal Carcinoma

    • Authors: Wenyue Duan, Xiong B, Tian T, Zou X, He Z, Ling Zhang
    • Year: 2022
    • Citations: Not provided

🔚 Conclusion

Zou Xinyun is a dedicated researcher and medical professional with a strong commitment to oncology and biomedical engineering. His contributions to cancer research, coupled with his clinical expertise, have earned him significant recognition in the medical field. With a solid track record of academic excellence, professional experience, and impactful publications, he continues to advance medical science and improve patient care.

Fizza Khalid | microbiology | Best Researchrer Award

Published on by Forensic Scientist

Dr. Fizza Khalid | microbiology | Best Researcher Award

clinical scientist at Dr Sulaiman Al-Habib Medical Diagnostic Laboratory , Saudi Arabia

Dr. Fizza Khalid is a dedicated microbiologist with extensive expertise in laboratory research, antimicrobial resistance, and clinical microbiology. With a Ph.D. in Medical Microbiology from the University of Health Sciences, Lahore, she has a proven track record of characterizing drug-resistant bacteria and developing innovative treatment strategies. Currently, she is the Deputy Head of the Clinical Research Committee and a Specialized Lab Supervisor at MD Lab, Dr. Sulaiman AlHabib Medical Group, Saudi Arabia. Dr. Khalid is passionate about advancing microbiological research to improve healthcare outcomes and has published several impactful studies in leading international journals.

Profile

ORCID

Educational

  • Ph.D. in Medical Microbiology (2016–2023) – University of Health Sciences, Lahore
    Thesis: Characterization of Locally Isolated Acinetobacter baumannii Strains for Drug Resistance and Biofilm Formation
  • M.Phil. in Medical Microbiology (2012–2014) – University of Health Sciences, Lahore
    Thesis: In-vitro Efficacy of Polymyxin B with Rifampin, Colistin, and Doxycycline Against Extensively Drug Resistant Acinetobacter baumannii
  • M.Sc. in Medical Technology (2008–2010) – University of Health Sciences, Lahore
    Thesis: Frequency of Extended Spectrum Beta Lactamase Enzymes in the Clinical Isolates of Salmonella Typhi
  • B.Sc. in Medical Laboratory Technology (2005–2007) – University of Health Sciences, Lahore

Professional Experience

Dr. Fizza Khalid currently serves as the Deputy Head of the Clinical Research Committee and Specialized Lab Supervisor in Microbiology at MD Lab, Dr. Sulaiman AlHabib Medical Group, Saudi Arabia. In her role, she leads clinical microbiology operations, collaborates with healthcare professionals, ensures regulatory compliance, and conducts research presented at international conferences. Previously, she was a Senior Lab Technologist at the same group, where she developed standard operating protocols, performed clinical microbiology analysis, and ensured testing quality and safety compliance. Throughout her career, Dr. Khalid has mentored junior researchers, promoted clinical research, and conducted workshops to enhance scientific study design and writing skills.

Research Interests

Dr. Khalid’s research focuses on antimicrobial resistance, particularly in Acinetobacter baum                                                                                             annii and Salmonella Typhi, biofilm formation, and the effectiveness of novel treatment strategies against drug-resistant bacterial strains. She has a keen interest in developing antimicrobial agents, studying bacterial genotyping, and investigating synergistic antibiotic combinations to combat multidrug-resistant pathogens. Her research contributes to understanding the molecular mechanisms of resistance and finding practical applications for improving patient care in clinical settings.

Author Metrics

  • Published Papers: 14 peer-reviewed articles, including journals such as Clinica Chimica Acta, JPMA, Scientific Reports, and Annals of Clinical Microbiology and Antimicrobials.
  • Citations: Her work has been widely cited in the fields of antimicrobial resistance and biofilm research.
  • H-index: Reflects her contributions to microbiology, particularly in research related to Acinetobacter baumannii and Salmonella Typhi.

Publication

Conclusion

Fizza Khalid presents an excellent case for the Best Researcher Award in medical microbiology, with notable strengths in antibiotic resistance research, an impressive publication record, and practical lab expertise. Her leadership role in facilitating junior researchers and fostering a culture of research also speaks to her broader contribution to the scientific community. With a few targeted improvements, such as securing international collaborations and focusing her research scope, she can further strengthen her candidacy for the award.

In conclusion, Khalid’s achievements in medical microbiology, particularly her work on MDR pathogens, make her a strong contender for the Best Researcher Award, demonstrating both scientific excellence and leadership in her field.